{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:23:37Z","timestamp":1788351817131,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer HealthCare AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011249","name":"Robert H Lurie Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.03.2244","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:34:47Z","timestamp":1776443687000},"page":"1683-1691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network\/Functional Assessment of Cancer Therapy Lymphoma Symptom Index in Patients With Lymphoma"],"prefix":"10.1016","volume":"29","author":[{"given":"Kimberly A.","family":"Webster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Zola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah A.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Devin","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jval.2026.03.2244_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2026.03.2244_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"11","key":"10.1016\/j.jval.2026.03.2244_bib4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials","volume":"111","author":"Kyte","year":"2019","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2026.03.2244_bib5","series-title":"Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders","year":"2023"},{"key":"10.1016\/j.jval.2026.03.2244_bib6","series-title":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.jval.2026.03.2244_bib7","series-title":"Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Guidance for Industry and Food and Drug Administration Staff, and Other Stakeholders","year":"2022"},{"key":"10.1016\/j.jval.2026.03.2244_bib8","series-title":"Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry","year":"2024"},{"key":"10.1016\/j.jval.2026.03.2244_bib9","series-title":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Guidance for Industry, FDA Staff, and Other Stakeholders","year":"2025"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-1-79","article-title":"The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2026.03.2244_bib11","series-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Guidance for Use in Research and Clinical Practice. Handbook of Quality of Life in Cancer","first-page":"79","author":"Webster","year":"2022"},{"key":"10.1016\/j.jval.2026.03.2244_bib12","series-title":"The Value of Innovation: Impact on Health, Life Quality, Safety, and Regulatory Research","article-title":"Development and validation of eleven symptom indexes to evaluate response to chemotherapy for advanced cancer: measurement compliance with regulatory demands","author":"Rosenbloom","year":"2007"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s41687-024-00752-6","article-title":"Content validation of the National Comprehensive Cancer Network\/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin\u2019s lymphoma","volume":"8","author":"Hurt","year":"2024","journal-title":"J Patient-Rep Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jval.2011.08.1739","article-title":"Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional assessment of cancer Therapy-Breast cancer symptom index (NFBSI-16)","volume":"15","author":"Garcia","year":"2012","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2244_bib15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/pon.1817","article-title":"Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN\/FACT-P Symptom Index","volume":"20","author":"Victorson","year":"2011","journal-title":"Psychooncol"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2244_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1634\/theoncologist.2009-0034","article-title":"Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness","volume":"15","author":"Colwell","year":"2010","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpainsymman.2012.06.004","article-title":"Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22)","volume":"46","author":"Pearman","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2244_bib18","first-page":"191","article-title":"Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cllc.2011.03.033","article-title":"A brief symptom index for advanced lung cancer","volume":"13","author":"Yount","year":"2012","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2244_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2010.09.025","article-title":"A new index of priority symptoms in advanced ovarian cancer","volume":"120","author":"Jensen","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jval.2013.11.006","article-title":"Development of a symptom index for patients with primary brain tumors","volume":"17","author":"Lai","year":"2014","journal-title":"Value Health"},{"issue":"6_suppl","key":"10.1016\/j.jval.2026.03.2244_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1200\/JCO.2021.39.6_suppl.408","article-title":"Reliability, validity, and clinically important differences (CIDs) on the NCCN\/FACT Bladder Symptom Index (NFBISI-18) among individuals with locally advanced or metastatic urothelial cancer (UC)","volume":"39","author":"Peipert","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jval.2026.03.2244_bib23","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1002\/cncr.27588","article-title":"Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI)","volume":"118","author":"Butt","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jval.2026.03.2244_bib24","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","article-title":"A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy\u2013Lymphoma Symptom Index","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib25","article-title":"The development and validation of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma: the functional assessment of cancer therapy\u2014lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"issue":"3","key":"10.1016\/j.jval.2026.03.2244_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.6004\/jnccn.2011.0026","article-title":"Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer","volume":"9","author":"Cella","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2244_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2020-0062","article-title":"Patient-reported outcomes in oncology clinical trials: stakeholder perspectives from the accelerating anticancer agent development and validation workshop 2019","volume":"25","author":"Bhatnagar","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.jval.2026.03.2244_bib28","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jval.2023.06.019","article-title":"Perspectives on patient-reported outcome data after treatment discontinuation in cancer clinical trials","volume":"26","author":"King-Kallimanis","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2244_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1353101","article-title":"Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review","volume":"14","author":"Oliva","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jval.2026.03.2244_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101953","article-title":"Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017-2022","volume":"59","author":"Ge","year":"2023","journal-title":"EClinicalmedicine"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2244_bib31","first-page":"338","article-title":"Indolent lymphoma: diagnosis and prognosis in medical practice","volume":"8","author":"Ciobanu","year":"2013","journal-title":"Maedica"},{"issue":"9844","key":"10.1016\/j.jval.2026.03.2244_bib32","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2026.03.2244_bib33","series-title":"Non-Hodgkin lymphoma Treasure Island (FL): StatPearls Publishing. StatPearls","author":"Sapkota","year":"2022"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2244_bib34","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/bjh.19860","article-title":"Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs","volume":"205","author":"Karsten","year":"2024","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.jval.2026.03.2244_bib35","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.3390\/cancers15174403","article-title":"Burden of illness in follicular lymphoma with multiple lines of treatment, Italian RWE analysis","volume":"15","author":"Ferreri","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2244_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies","volume":"11","author":"Cheson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2244_bib37","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.03.2244_bib38","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2021-150873","article-title":"Duration of objective responses for patients with indolent non-Hodgkin lymphoma discontinuing treatment before progression: analysis from the Phase III Chronos-3 trial comparing copanlisib plus rituximab with placebo plus rituximab","volume":"138","author":"Matasar","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jval.2026.03.2244_bib39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jval.2026.03.2244_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11136-018-2076-0","article-title":"Assessing test\u2013retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula","volume":"28","author":"Qin","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2026.03.2244_bib41","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"2003"},{"key":"10.1016\/j.jval.2026.03.2244_bib42","series-title":"Statistical Power Analysis for the Behavioral Science","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1016\/j.jval.2026.03.2244_bib43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores","volume":"27","author":"Coon","year":"2018","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jval.2026.03.2244_bib44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jval.2026.03.2244_bib45","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s11136-022-03200-4","article-title":"Likely change indexes improve estimates of individual change on patient-reported outcomes","volume":"32","author":"Peipert","year":"2023","journal-title":"Qual Life Res"},{"issue":"12","key":"10.1016\/j.jval.2026.03.2244_bib46","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s11136-024-03788-9","article-title":"Significant individual change should be used as a lower bound for anchor based estimates of meaningful change on patient-reported outcome scores","volume":"33","author":"Peipert","year":"2024","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2026.03.2244_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-4-70","article-title":"Responsiveness and minimal important differences for patient reported outcomes","volume":"4","author":"Revicki","year":"2006","journal-title":"Health Qual Life Outcomes"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:08:45Z","timestamp":1788350925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526023880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1098301526023880"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2244","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network\/Functional Assessment of Cancer Therapy Lymphoma Symptom Index in Patients With Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}